Bylavy

Chemical Nameodevixibat
Dosage FormPellet (oral; 200 mcg, 600 mcg); Capsule (oral; 400 mcg, 1200 mcg)
Drug ClassInhibitors
SystemDigestive
CompanyAlbireo
Approval Year2021

Indication

  • For the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC)
Last updated on 3/15/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Bylavy (odevixibat) Prescribing Information.2021Albireo Pharma Inc., Boston, MA